Literature DB >> 27150639

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study.

Mark W Ball1, Michael A Gorin2, Gunes Guner3, Phillip M Pierorazio2, George Netto3, Channing J Paller4, Hans J Hammers4, Luis A Diaz4, Mohamad E Allaf2.   

Abstract

Entities:  

Keywords:  Biomarker; Cell-free DNA; Kidney cancer; Next-generation sequencing; Treatment response

Mesh：

Substances：

Year:  2016        PMID： 27150639      PMCID： PMC5035558          DOI： 10.1016/j.clgc.2016.03.019

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  10 in total

1.  Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study.

Authors:  Stefan Hauser; Tobias Zahalka; Guido Fechner; Stefan C Müller; Jörg Ellinger
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

Review 2.  A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

Authors:  Laurence Albiges; Toni Choueiri; Bernard Escudier; Matthew Galsky; Dan George; Fabian Hofmann; Thomas Lam; Robert Motzer; Peter Mulders; Camillo Porta; Thomas Powles; Cora Sternberg; Axel Bex
Journal:  Eur Urol       Date:  2014-05-01       Impact factor: 20.096

3.  Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.

Authors:  Jose M Silva; Javier Silva; Antonio Sanchez; Jose M Garcia; Gemma Dominguez; Mariano Provencio; Luis Sanfrutos; Eugenia Jareño; Antonio Colas; Pilar España; Felix Bonilla
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

4.  Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer.

Authors:  Stefan Hauser; Tobias Zahalka; Jörg Ellinger; Guido Fechner; Lukas C Heukamp; Alexander VON Ruecker; Stefan C Müller; Patrick J Bastian
Journal:  Anticancer Res       Date:  2010-07       Impact factor: 2.480

5.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Circulating mutant DNA to assess tumor dynamics.

Authors:  Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Nat Med       Date:  2007-07-31       Impact factor: 53.440

7.  Analysis of circulating tumor DNA to monitor metastatic breast cancer.

Authors:  Sarah-Jane Dawson; Dana W Y Tsui; Muhammed Murtaza; Heather Biggs; Oscar M Rueda; Suet-Feung Chin; Mark J Dunning; Davina Gale; Tim Forshew; Betania Mahler-Araujo; Sabrina Rajan; Sean Humphray; Jennifer Becq; David Halsall; Matthew Wallis; David Bentley; Carlos Caldas; Nitzan Rosenfeld
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

Review 8.  Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations.

Authors:  Axel Bex; Laure Fournier; Nathalie Lassau; Peter Mulders; Paul Nathan; Wim J G Oyen; Thomas Powles
Journal:  Eur Urol       Date:  2013-11-28       Impact factor: 20.096

9.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

10.  Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?

Authors:  Evelyn Kidess; Stefanie S Jeffrey
Journal:  Genome Med       Date:  2013-08-13       Impact factor: 11.117
  10 in total
  9 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

Review 2.  The Role of Circulating Tumor DNA in Renal Cell Carcinoma.

Authors:  Paulo G Bergerot; Andrew W Hahn; Cristiane Decat Bergerot; Jeremy Jones; Sumanta Kumar Pal
Journal:  Curr Treat Options Oncol       Date:  2018-02-20

3.  Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.

Authors:  Ritesh R Kotecha; Erika Gedvilaite; Ryan Ptashkin; Andrea Knezevic; Samuel Murray; Ian Johnson; Natalie Shapnik; Darren R Feldman; Maria I Carlo; Neil J Shah; Marisa Dunigan; Kety Huberman; Ryma Benayed; Ahmet Zehir; Michael F Berger; Marc Ladanyi; Dana W Y Tsui; Robert J Motzer; Chung-Han Lee; Martin H Voss
Journal:  JCO Precis Oncol       Date:  2022-07

Review 4.  Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Simona Tavolari; Giovanni Brandi
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 5.  Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.

Authors:  Ronan Flippot; Bernard Escudier; Laurence Albiges
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

6.  Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).

Authors:  Wenxin Xu; Mäneka Puligandla; Brian Halbert; Naomi B Haas; Keith T Flaherty; Robert G Uzzo; Janice P Dutcher; Robert S DiPaola; Venkata Sabbisetti; Rupal S Bhatt
Journal:  Clin Cancer Res       Date:  2021-04-08       Impact factor: 12.531

Review 7.  Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy.

Authors:  Alessia Cimadamore; Silvia Gasparrini; Francesco Massari; Matteo Santoni; Liang Cheng; Antonio Lopez-Beltran; Marina Scarpelli; Rodolfo Montironi
Journal:  Cancers (Basel)       Date:  2019-02-07       Impact factor: 6.639

Review 8.  Decision-making in active surveillance in kidney cancer: current trends and future urine and tissue markers.

Authors:  Sunil H Patel; Nirmish Singla; Phillip M Pierorazio
Journal:  World J Urol       Date:  2021-08-09       Impact factor: 4.226

Review 9.  Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature.

Authors:  Louise Geertsen; Kristina Magaard Koldby; Mads Thomassen; Torben Kruse; Lars Lund
Journal:  Eur Urol Open Sci       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.